The LCCC internal and external advisory groups provided invaluable guidance in planning and evaluation of all the major initiatives. The new Director continued to expand the decision-making and advisory groups to include: The Senior Leadership Team, which is composed of the Director and (8) Associate Directors,meets weekly to evaluate progress in strategic LCCC initiatives. The Program Planning Committee, which meets bi-weekly to evaluate progress of all important initiatives and includes institutional and Research Program Leaders, plus the Senior Leadership Team. The Internal Advisory Board, which is comprised of institutional leaders including the Chancellor; the Deans of the schools of Medicine, Pharmacy, and Public Health; and external advisors, and which meets with the Director at least quarterly. The Scientific Advisory Board (SAB), which is comprised of expert external advisors, and which was expanded with the addition of 7 new members in 2014 to provide additional expertise in specific areas such as cancer genomics, tumor immunology, administration, patient advocacy and biostatistics. There are now 16 members on the SAB with complementary expertise in basic, clinical, translational, and population sciences and administration. The SAB meets annually or more often, at the UNC LCCC. With careful planning and critical input from advisory groups, the Director initiated a new 5 year strategic planning process, reorganized Center Research Program membership, Shared Resource Leadership, and created working groups and committees to continue improving oversight and governance. These coordinated teams of advisors provide critical advice and guidance, both annually in the fall and ad-hoc as required, ensuring that LCCC most effectively set priorities and pursues objectives that promote basic, clinical, prevention and translational research at the Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-42
Application #
9391960
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
42
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications